PMC:7195088 / 18158-18359 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"761","span":{"begin":139,"end":158},"obj":"Chemical"},{"id":"923","span":{"begin":1,"end":9},"obj":"Disease"}],"attributes":[{"id":"A761","pred":"tao:has_database_id","subj":"761","obj":"MESH:C558899"},{"id":"A923","pred":"tao:has_database_id","subj":"923","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T89","span":{"begin":1,"end":9},"obj":"Disease"}],"attributes":[{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T93","span":{"begin":16,"end":21},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":" COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T151","span":{"begin":16,"end":21},"obj":"Chemical"},{"id":"T152","span":{"begin":139,"end":158},"obj":"Chemical"},{"id":"T153","span":{"begin":139,"end":148},"obj":"Chemical"},{"id":"T154","span":{"begin":149,"end":158},"obj":"Chemical"},{"id":"T155","span":{"begin":172,"end":182},"obj":"Chemical"},{"id":"T157","span":{"begin":192,"end":201},"obj":"Chemical"}],"attributes":[{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"}],"text":" COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir"}

{"project":"LitCovid-sentences","denotations":[{"id":"T121","span":{"begin":11,"end":60},"obj":"Sentence"},{"id":"T122","span":{"begin":61,"end":122},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir"}